Arvinas is a clinical-stage biopharmaceutical company at the forefront of developing a new class of medicines based on targeted protein degradation. Utilizing its proprietary PROTAC® (PROteolysis TArgeting Chimera) platform technology, Arvinas aims to harness the body's natural protein disposal system to selectively and efficiently remove disease-causing proteins. The company's primary focus is on creating novel treatments for cancers and other debilitating diseases with high unmet medical needs. Arvinas is advancing a pipeline of product candidates in multiple therapeutic areas, including oncology and neuroscience.
The New Haven headquarters serves as the central hub for Arvinas's research and development, clinical operations, and corporate functions.
State-of-the-art laboratory facilities, collaborative workspaces designed to foster innovation, located within the Science Park at Yale, a vibrant bioscience cluster.
Arvinas fosters a dynamic and innovative work environment. The culture is rooted in scientific rigor, collaboration across diverse teams, and a shared mission to impact patient lives. The atmosphere is intellectually stimulating, encouraging cutting-edge research in protein degradation.
The headquarters' location provides access to a rich talent pool, academic collaborations (including proximity to Yale University), and a supportive biotech ecosystem, crucial for Arvinas's pioneering research and development efforts.
While Arvinas's primary R&D and corporate operations are centered in the U.S. (New Haven, CT), the company maintains a global reach through its clinical trials conducted across North America, Europe, and Asia-Pacific. It also operates a research center in Suzhou, China, to support its discovery efforts. Furthermore, Arvinas engages in strategic collaborations with global pharmaceutical partners to advance its pipeline and technology platform.
5 Science Park
New Haven
CT
USA
Address: Arvinas Protein Degradation Research Center Co., Ltd., Building C17, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China
To tap into the growing scientific talent and research capabilities in China, expand global research footprint, and accelerate the discovery phase of novel protein degraders.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Arvinas' leadership includes:
Arvinas has been backed by several prominent investors over the years, including:
Arvinas has strategically strengthened its leadership team over the past 12 months with key appointments in legal and commercial functions, aligning with its progression as a clinical-stage company preparing for potential product launches. No major executive departures were publicly highlighted during this period.
Discover the tools Arvinas uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Arvinas commonly uses the 'first.last' email format. Variations might exist, but this is the most frequently observed pattern for company communications.
firstname.lastname@arvinas.com
Format
john.doe@arvinas.com
Example
85%
Success rate
Arvinas, Inc. • May 9, 2024
Arvinas announced its financial results for the first quarter of 2024 and provided updates on its pipeline programs, including progress on its PROTAC® protein degraders vepdegestrant (ARV-471) and ARV-766....more
Arvinas, Inc. • May 7, 2024
Arvinas highlighted multiple presentations featuring new data and analyses for its novel estrogen receptor PROTAC® degrader, vepdegestrant, at the ESMO Breast Cancer 2024....more
Arvinas, Inc. • April 8, 2024
Arvinas announced plans to present preclinical data for its innovative KRAS G12C PROTAC® protein degrader program, showcasing its potential in targeting this challenging oncogene....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Arvinas, are just a search away.